Cormorant Asset Management LP 13D and 13G filings for Tarsus Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 3:05 pm Sale |
2024-09-30 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Cormorant Asset Management LP | 500,000 1.310% |
-1,721,422 (-77.49%) |
Filing |
| 2024-02-14 3:04 pm Purchase |
2023-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Cormorant Asset Management LP | 2,221,422 6.710% |
485,000 (+27.93%) |
Filing |
| 2023-02-14 3:04 pm Purchase |
2022-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Cormorant Asset Management LP | 1,736,422 6.510% |
333,091 (+23.74%) |
Filing |
| 2022-02-14 3:01 pm Sale |
2021-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Cormorant Asset Management LP | 1,403,331 6.790% |
-310,938 (-18.14%) |
Filing |
| 2021-02-16 3:34 pm Sale |
2020-12-31 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Cormorant Asset Management LP | 1,714,269 8.450% |
-249,999 (-12.73%) |
Filing |
| 2020-10-30 4:00 pm Purchase |
2020-10-20 | 13G | Tarsus Pharmaceuticals, Inc. TARS |
Cormorant Asset Management LP | 1,964,268 9.780% |
1,964,268 (New Position) |
Filing |